Anthropic disclosed that an unreleased research Claude model raised the proven fraction of zeta zeros on the critical line from 41.6% to 67.2%, the largest single-step jump in history, using 60 AI sub ...

~ Integer Stockholders to Receive $127 Per Share in Cash ~ ~ Agreement Follows Comprehensive, Board-Led Strategic Review ~ ~ Transaction to Advance Integer’s Innovation and Growth in Support of ...

Investment firm KKR KKR1.18%increase; up pointing triangle has struck a deal to acquire medical-device outsourcing company Integer Holdings ITGR-0.15%decrease; down pointing triangle for about $4.3 ...

Private equity giant KKR will take Integer Holdings private in an all-cash deal valued at about $5.7 billion, the medical-device outsourcing firm said on Monday. Shares of Plano, Texas-based Integer ...

July 31 (Reuters) - Private equity firm KKR (KKR.N), opens new tab is nearing a takeover of medical device outsourcing company Integer Holdings (ITGR.N), opens new tab, the Wall Street ‌Journal ...

Patrick Mahomes says cleared for full camp, yet NFL betting guide cites 14 games: 22 TD, 11 INT; Chiefs offense 21st at 21.3 PPG. Tropical storm Moke to impact US this weekend: Live tracker maps, path ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Private equity group KKR is nearing a more than $4bn take-private deal for a medical device maker recently ...

MIAMI GARDENS — Dolphins quarterbacks threw four interceptions Friday, but two could be blamed on wide receivers. But let’s also give credit to the defensive backs, led by little-known cornerback ...

Cornerback Jarrian Jones stood out with two interceptions, one against quarterback Trevor Lawrence in red zone drills. The team experimented with its offensive line, moving Anton Harrison to left ...

FOXBORO — Three plays, three picks. One hootering, hollering, happy-as-could-be sideline. Mike Vrabel closed shop a few minutes early Thursday amid soaring temperatures and an even hotter Patriots ...

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its ...